WASHINGTON (Reuters) - An experimental drug made by Pfizer to treat the common cold may provide a starting point for finding a treatment for SARS, researchers in Germany said on Tuesday. The compound, known only by its laboratory name AG7088, is not likely to itself be a treatment for severe acute respiratory syndrome, said Rolf Hilgenfeld of the University of Luebeck in Germany, who led the study. "There are some minor clashes between the inhibitor AG7088 and the structure of SARS coronavirus main protease; therefore, this compound, AG7088, is unlikely to be a drug active against coronavirus infections," Hilgenfeld said...